The FDA has accepted the supplemental Biologics License Application (BLA) for ropeginterferon alfa-2b-njft (Besremi), a ...
Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.
New research has exposed AML's reliance on a specific signaling pathway involved in the body's inflammation response, ...
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and ...
Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...
BBC Radio 2 presenter Sara Cox has shared a formula that costs 86p per day and has helped her signature fringe flourish. Cox, who is an ambassador for Dr Vegan, has shared the impact using the brand's ...
MedPage Today on MSN
CAR-T immune toxicity linked to non-relapse mortality risk in myeloma
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
Olatec Therapeutics, Inc. ("Olatec"), a clinical stage biotechnology company leading the development of specific NLRP3 inhibitors, presented preclinical data at The Michael J. Fox Foundation (MJFF) ...
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from ...
The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumors respond to cancer immunotherapy and could be used ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback